TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06375135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TXTXT
Description: Treatment Text (TXTXT) is composed of personalized 2-way SMS text message reminders and encouraging messages. Daily text message reminders will be sent according to the participants medication schedule for six months. A study coordinator will enter the participants phone number in the TXTXT system and set the program to provide daily reminders at the time consistent with the clinical dosing schedule of their ART. Participants will have the option of choosing to create a personalized message that may be changed at any time, because the messages are personalized, they may be in any language the participant desires. Fifteen minutes after this initial message, participants will be asked to send a text message response indicating if they took their medications. Participants responses will be followed by one of a set of randomly selected encouraging messages depending on their affirmative or negative response.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TXTXT
Description: Treatment Text (TXTXT) is composed of personalized 2-way SMS text message reminders and encouraging messages. Daily text message reminders will be sent according to the participants medication schedule for six months. A study coordinator will enter the participants phone number in the TXTXT system and set the program to provide daily reminders at the time consistent with the clinical dosing schedule of their ART. Participants will have the option of choosing to create a personalized message that may be changed at any time, because the messages are personalized, they may be in any language the participant desires. Fifteen minutes after this initial message, participants will be asked to send a text message response indicating if they took their medications. Participants responses will be followed by one of a set of randomly selected encouraging messages depending on their affirmative or negative response.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Navigation
Description: Develop an e-Navigation intervention using all three components of CDCs STEPS to Care intervention:(1) patient navigation, (2) care coordination, and (3) HIV-self-management.~Patient Navigation: Remote one-on-one sessions, will help improve medication adherence, access to social services, and prompt re-engagement in care.~Care coordination: Frequent and open communication with the care team. E-navigator will share client progress and needs, support information-sharing and decision-making to improve health outcomes for clients.~HIV self-management: HIV education and guidance with goal setting. E-navigator will help clients build knowledge and skills for self-care, navigating the health care system, and independent health maintenance.~The e-Navigator will meet with participants bi-weekly at first but may meet less frequently over time as barriers are addressed. Meetings will be conducted via videoconferencing and will be used to check in and provide individualized support.
Study: NCT05367661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHK336
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHK336
Description: Tablet
Study: NCT05190432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ergothioneine
Description: An amino acid found in mushrooms, oats and some bean varieties.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Microcrystalline cellulose.
Study: NCT05900154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF 120 µg
Description: RSVpreF standard dose level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF 120 µg
Description: RSVpreF standard dose level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF 120 µg
Description: RSVpreF standard dose level
Study: NCT05367661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHK336
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHK336
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study: NCT04656483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Video Feedback Intervention
Description: Mother-child dyads will take part into a 6 video-conference sessions of Video Feedback (vVF). The vVF will be standardized according to previously published RCTs. Specifically, the 6 vVFI sessions will be organized in two subsequent phases: 4 sessions based on sharing the focus on different relational themes, and 2 sessions of interactive integration. In more specific terms, during the first set of 4 sessions the psychologist will review with mothers' segments of the videotapes obtained during the baseline assessment and will focus on four different relational themes: responsiveness, physical stimulation, teaching, and parenting experience. During the interactive integration session, the insights developed from the first 4 videoconferences will be applied to the real-time interaction between the parent and his/her infant under the guidance of the psychologist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Booklet Intervention
Description: Mothers of this condition will receive an informative booklet addressing the same themes included in the experimental intervention (responsiveness, physical stimulation, teaching, and parenting experience), but not tailored on their own infant status.
Study: NCT01589627

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Extension Dynasplint
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
Study: NCT05834595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D064, D701
Description: QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828, D064, D701
Description: QD, PO
Study: NCT05929820

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protect Your Colon™
Description: Protect Your Colon™ is an online decision aid focused on CRC screening. The site will first educate patients on the importance of CRC screening and offer information on the advantages and disadvantages of the available test options. Protect Your Colon™ will then present an interactive conjoint analysis-a quantitative survey technique that elucidates how individuals make complex decisions-to precisely determine individuals' latent preferences regarding CRC screening options. Afterwards, the app will generate a personalized report that rank orders the importance of each test attribute (e.g., accuracy, invasiveness, test frequency) in patients' decision making and identifies the screening modality that best matches their preferences. The report will also be shareable with physicians, enabling patients and providers to engage in shared decision making surrounding CRC screening in the clinic.
Study: NCT05884632

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Daily Adaptive RadioTherapy
Description: Patients will be treated on the prostate bed with Ethos using daily-adaptive modality with the dose of 59 Gy in 20 daily fractions of 2.95 Gy
Study: NCT05954039

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Polar Lipid Complex
Description: The study foresees the intake of 2 capsules per day during 84 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 2 capsules per day during 84 days
Study: NCT05900154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF 60 µg
Description: RSVpreF low dose level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF 60 µg
Description: RSVpreF low dose level

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF 60 µg
Description: RSVpreF low dose level
Study: NCT06380244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anesthesia without opioids
Description: Opioid free general anesthesia
Study: NCT06404528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood glucose stress combined with low-dose chemotherapy
Description: By controlling the patient's blood sugar, low-dose chemotherapy is used in a hypoglycemic state. Some necrotic tumor cells produced by chemotherapy can maintain their immunogenicity, further activate innate immunity, produce very strong anticancer effects, and have no cytotoxic reactions to chemotherapy.
Study: NCT05303285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 300mg s.c.
Description: Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 300 mg secukinumab s.c. every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab 150mg s.c.
Description: Induction: 5 x 150 mg secukinumab s.c. weekly. Maintenance: 150 mg secukinumab s.c. every 4 weeks
Study: NCT05707325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: engineered red blood cell
Description: engineered red blood cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: engineered red blood cell
Description: engineered red blood cell
Study: NCT06375135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Navigation
Description: Develop an e-Navigation intervention using all three components of CDCs STEPS to Care intervention:(1) patient navigation, (2) care coordination, and (3) HIV-self-management.~Patient Navigation: Remote one-on-one sessions, will help improve medication adherence, access to social services, and prompt re-engagement in care.~Care coordination: Frequent and open communication with the care team. E-navigator will share client progress and needs, support information-sharing and decision-making to improve health outcomes for clients.~HIV self-management: HIV education and guidance with goal setting. E-navigator will help clients build knowledge and skills for self-care, navigating the health care system, and independent health maintenance.~The e-Navigator will meet with participants bi-weekly at first but may meet less frequently over time as barriers are addressed. Meetings will be conducted via videoconferencing and will be used to check in and provide individualized support.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA) supported e-Navigation.
Description: Participants in the Ecological Momentary Assessment (EMA) supported e- Navigation intervention will be asked to complete 4 to 6-minute EMAs via a secure survey link three times per week to assess adherence barriers in real or near real time. In addition to time-based EMA (study prompted), participants will also be able to submit event based EMAs (participant prompted) at any time. The e-Navigator will review responses to EMAs and remotely assist participants in addressing these barriers within 2 business days.
Study: NCT06283108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Child Life Preparation and Support + Meta Quest 2 VR headset with Gurney Journey (a mixed reality experience)
Description: Certified Child Life Specialist's will provide preparation and support for patients before and during their anesthesia induction for their dental procedure. Child life specialist's will utilize Gurney Journey as part of their support for induction. Gurney Journey is a mixed reality experience, using the Meta Quest 2 VR headset that was designed to mitigate patient anxiety during transport from pre-admission rooms to the procedure room/operating room for surgical procedures.
Study: NCT06472128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DREAMLAND
Description: Participants assigned to DREAMLAND will start using DREAMLAND during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VITAL WELLNESS
Description: Participants assigned to VITAL WELLNESS will start using VITAL WELLNESS during the first week of their hospitalization, with a suggested timeline of reviewing one module each week to complete the required modules by week 4 of their hospital stay.
Study: NCT05050474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Fusion Protein Vaccine
Description: The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
Study: NCT06153862

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immuno analytical assay
Description: The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Immuno analytical assay
Description: The eluted antibodies will be used in immuno-analytical assays, such as ELISA or Western blot, or surface-coated bead-based screening platforms using either recombinantly produced MSP119 fusion protein or synthetic peptides derived from MSP119 as antigens according to standard protocols.
Study: NCT06283108

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Child Life Preparation and Support
Description: Certified Child Life Specialist's will provide preparation and support for patients before and during their anesthesia induction for their dental procedure.
Study: NCT06007443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pain related variables assessment
Description: Pressure pain threshold, conditioned pain modulation, temporal summation, and two-point discrimination will be evaluated on the upper trapezius muscle. Average pain intensity will be asked.
Study: NCT05713448

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06264622

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose
Description: 2 tablets per day during the morning for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose
Description: 2 tablets per day during the morning for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets per day during the morning for 12 weeks.
Study: NCT04939584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiPulse Therapy
Description: Electrical Stimulation
Study: NCT06415331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency
Description: Individualized dose of pulsed radiofrequency is given for 6 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Conventional therapy for HNP consisting of:~* Acetaminophen~* NSAID: Etoricoxib, celecoxib, meloxicam, diclofenac, ibuprofen~* Muscle relaxant: eperisone, diazepam~* Opioid: codein, tramadol~* Adjuvant analgesics: Amitriptyline, pregabalin, gabapentin~* Physiotherapy: Short wave diathermy, ultrasound diathermy, transcutaneous electrical nerve stimulation, and exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Conventional therapy for HNP consisting of:~* Acetaminophen~* NSAID: Etoricoxib, celecoxib, meloxicam, diclofenac, ibuprofen~* Muscle relaxant: eperisone, diazepam~* Opioid: codein, tramadol~* Adjuvant analgesics: Amitriptyline, pregabalin, gabapentin~* Physiotherapy: Short wave diathermy, ultrasound diathermy, transcutaneous electrical nerve stimulation, and exercise
Study: NCT05693220

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zymot Multi sperm separation device
Description: Sperm preparation with Zymot Multi sperm preparation device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Density gradient centrifugation
Description: Sperm preparation with density gradient centrifugation
Study: NCT05021224

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Rapidly prototype and test strategies
Description: We will generate strategies for facilitating treatment initiation that address barriers and leverage facilitators, in partnership with a team of experts in behavioral science and implementation science. We will favor simple, established strategies with freely available resources (e.g., Caring Contacts templates) to promote scalability, but will also consider other potential strategies as indicated. We will explore both low- (e.g., manualized text messaging) and high-tech (e.g., electronic health record integrated patient messaging) strategies to maximize relevance across contexts. Next, prototype-strategy designs will be validated through rapid-cycle tests in this real world context and in a manner that is inexpensive and allows us to fail fast and learn quickly. After testing a given implementation strategy, the team will debrief and decide whether to refine or adjust it.
Study: NCT06519929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block with catheter using ropivacaine (bolus followed by continuous infusion)
Description: A total of ropivacaine 75mg will be injected into the plane via the needle, followed by placement of a catheter 3-5 cm into the plane. A continuous infusion of ropivacaine 0.2% will be started at 8 mL/h and may be titrated up to a maximum of 10mL/h. Bolus doses of 5 mL using ropivacaine 0.2% will be permitted for breakthrough pain (pain score ≥ 7/10) and may be administered no more frequently than every 6 hours. Patients will be assessed for LAST twice daily by asking about tinnitus, perioral numbness, or metallic taste. Any patient who responds positively to these symptoms will have infusion stopped for 2 h and then restarted at a rate 2 mL/h lower. If the symptoms occur again, the catheter infusion will be stopped and the catheter removed. After the 72-hour study period the ESP catheter may remain in place if the patient has ongoing analgesia needs or if analgesia is controlled with oral medication the catheter may be removed at request of the treating team.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine bolus (1 mg/kg) and infusion starting at 1 mg/kg/h
Description: A bolus of 1 mg/kg based on ideal body weight will be given over 10 minutes with a physician present and infusions will be started at 1 mg/kg/h based on IBW. Infusions will run continuously for the first 72 h and can be continued beyond that at the discretion of the treating team if pain persists. Patients will be assessed for LAST twice daily. Any patient with suspected LAST will have lidocaine infusion stopped and a lidocaine plasma level will be sent. If symptoms resolve, the lidocaine infusion can be restarted at a rate 25% lower. If pain is refractory to the lidocaine infusion and multimodal adjuncts, the infusion may be increased to a maximum of 1.5 mg/kg/h (during first 24 h only). The actual duration of the infusion as well as total lidocaine dose given in mg will be recorded. Stopping criteria for lidocaine will include the occurrence of new EKG changes for which an alternative explanation is not more likely as well as LAST symptoms.
Study: NCT05998447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN-001
Description: The capsules taken by mouth. Each capsule will contain ≥ 3x10\^11 colony-forming units (CFU)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg given by intravenous (IV) infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: mFOLFOX given by intravenous (IV) once every 2 weeks for only cohort 3
Study: NCT05708651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational device [I-IV]
Description: Intra-individual randomised paired crossover evaluation of airway patency with investigational device in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep steady-state sedation \[I-II\] or procedural sedation according to SOC \[III-IV\].

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator [I-IV]
Description: Intra-individual randomised paired crossover evaluation of airway patency with comparator (biteblock \[I-II\] or no device \[II-IV\]) in volunteer study participants \[I-II\] and study patients \[III-IV\] at low, moderate and deep levels of steady-state sedation \[I-II\], and during procedural sedation according to SOC for scheduled colonoscopy \[III\] or ureteral catheterization \[IV\].
Study: NCT06504381

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DB107-RRV
Description: Given intracranially (IC) during resection and intravenously (IV) immediately following
Study: NCT05773781

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PuraBond
Description: Application of PuraBond to surgical field
Study: NCT06321250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003948
Description: Subjects will receive JMKX003948 tablets until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003948
Description: Subjects will receive JMKX003948 tablets until disease progression
Study: NCT06504381

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DB107-RRV
Description: Given intracranially (IC) during resection and intravenously (IV) immediately following

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DB107-FC
Description: Given orally (PO)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DB107-FC
Description: Given orally (PO)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo RT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Undergo RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo standard of care MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo standard of care MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Undergo non-investigational tumor resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Undergo non-investigational tumor resection
Study: NCT06651567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1284
Description: ITI-1284 10 mg or 20 mg rapidly disintegrating tablet, taken once daily, sublingual administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo rapidly disintegrating tablet, taken once daily, sublingual administration